Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
1999 1
2000 2
2001 1
2002 1
2004 4
2005 1
2006 1
2007 1
2008 2
2009 5
2010 2
2011 4
2012 5
2013 4
2014 4
2015 7
2016 5
2017 1
2018 3
2020 3
2021 3
2022 3
2023 5
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Rosée P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, Gørløv JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G; IELSG32 study investigators. Ferreri AJM, et al. Among authors: ilariucci f. Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13. Leukemia. 2022. PMID: 35562406 Clinical Trial.
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.
Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C, Re F, Fanni A, Singh V, Bromberg JEC, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E, Cwynarski K; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJM, et al. Among authors: ilariucci f. Lancet Haematol. 2021 Feb;8(2):e110-e121. doi: 10.1016/S2352-3026(20)30366-5. Lancet Haematol. 2021. PMID: 33513372 Free PMC article. Clinical Trial.
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Among authors: ilariucci f. Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1. Epub 2009 Sep 18. Lancet. 2009. PMID: 19767089 Free article. Clinical Trial.
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJM, et al. Among authors: ilariucci f. Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17. Lancet Haematol. 2017. PMID: 29054815 Clinical Trial.
Primary Vitreoretinal Lymphoma: Current Diagnostic Laboratory Tests and New Emerging Molecular Tools.
Melli B, Gentile P, Nicoli D, Farnetti E, Croci S, Gozzi F, Bolletta E, De Simone L, Sanguedolce F, Palicelli A, Zizzo M, Ricci S, Ilariucci F, Rossi C, Cavazza A, Ascani S, Cimino L, Zanelli M. Melli B, et al. Among authors: ilariucci f. Curr Oncol. 2022 Sep 24;29(10):6908-6921. doi: 10.3390/curroncol29100543. Curr Oncol. 2022. PMID: 36290820 Free PMC article. Review.
Artificial Intelligence-Assisted Processing of Anterior Segment OCT Images in the Diagnosis of Vitreoretinal Lymphoma.
Gozzi F, Bertolini M, Gentile P, Verzellesi L, Trojani V, De Simone L, Bolletta E, Mastrofilippo V, Farnetti E, Nicoli D, Croci S, Belloni L, Zerbini A, Adani C, De Maria M, Kosmarikou A, Vecchi M, Invernizzi A, Ilariucci F, Zanelli M, Iori M, Cimino L. Gozzi F, et al. Among authors: ilariucci f. Diagnostics (Basel). 2023 Jul 23;13(14):2451. doi: 10.3390/diagnostics13142451. Diagnostics (Basel). 2023. PMID: 37510195 Free PMC article.
Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
Chiappella A, Dodero A, Evangelista A, Re A, Orsucci L, Usai SV, Castellino C, Stefoni V, Pinto A, Zanni M, Ciancia R, Ghiggi C, Rossi FG, Arcari A, Ilariucci F, Zilioli VR, Flenghi L, Celli M, Volpetti S, Benedetti F, Ballerini F, Musuraca G, Bruna R, Patti C, Leonardi F, Arcaini L, Magagnoli M, Cavallo F, Bermema A, Tucci A, Boccomini C, Ciccone G, Carniti C, Pileri SA, Corradini P. Chiappella A, et al. Among authors: ilariucci f. Leukemia. 2023 Feb;37(2):433-440. doi: 10.1038/s41375-022-01780-1. Epub 2023 Jan 18. Leukemia. 2023. PMID: 36653509 Free PMC article. Clinical Trial.
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: ilariucci f. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
59 results